Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

AI-generated analysis

🏆 Regeneron Pharmaceuticals has been named to the Dow Jones Best-in-Class World Index for Global Responsibility Leadership for seven consecutive years.

🌍 The company also earns a spot on the Dow Jones Best-in-Class North America Index for six consecutive years as one of only four recognized U.S. biotechnology firms.

🔬 These distinctions reflect Regeneron's long-term commitment to embed responsibility into every dimension of its business, from drug discovery to operations.

💊 This recognition complements Regeneron's recent announcement to provide a new gene therapy for congenital hearing loss free of charge in the United States.

🎯 New science-led 2030 responsibility goals were introduced to drive responsible innovation and sustainable growth for the business and humanity.

📈 CEO Leonard S. Schleifer stated that being recognized by the Dow Jones Indices reflects their philosophy of "Doing Well by Doing Good."

📊 Regeneron's new 2025 Responsibility Report highlights progress against goals, noting the company met or surpassed nearly all targets for that period.

🎓 The company's primary philanthropic focus is the STEM-Fueled™ initiative, which aims to cultivate the next generation of scientific leaders.

🧪 Since 2020, Regeneron has provided over four million STEM experiences to students through various competitive science programs.

🥇 Regeneron serves as the title sponsor for the Science Talent Search and the International Science and Engineering Fair with a $300 million commitment through 2036.

🤝 The Together for CHANGE™ initiative partners with Meharry Medical College and others to address inequities in STEM careers and genomics research.

📈 Regeneron ranks in the top 10% of its industry across major ESG ratings from S&P Global, Sustainalytics, and ISS ESG.

📰 The company has also been listed on Newsweek's America's Most Responsible Companies for seven consecutive years.

⏳ Regeneron is named to TIME's World's Most Sustainable Companies list for the second consecutive year.

💉 Founded and led by physician-scientists, Regeneron develops medicines for serious diseases including eye, cancer, neurological, and rare conditions.

🧬 The company utilizes proprietary technologies like VelociSuite® to produce fully human antibodies and new classes of bispecific antibodies.

🧠 Data-powered insights from the Regeneron Genetics Center enable the identification of innovative targets to treat or cure diseases.

Bullish Signals
  • Regeneron has been named to the Dow Jones Best-in-Class World Index for seven consecutive years, becoming one of only eight biotechnology companies globally included in this prestigious benchmark.
  • The company secured a spot on the Dow Jones Best-in-Class North America Index for six consecutive years, distinguishing itself as one of just four U.S.-based biotechnology firms recognized.
  • Regeneron announced it will provide its new gene therapy for a specific form of congenital hearing loss for free in the United States, reinforcing its commitment to patient access and affordability.
  • The company introduced new science-led 2030 responsibility goals that demonstrate a strong foundation for sustainable growth and responsible innovation in medicine development.
  • Regeneron is meeting or surpassing nearly all of its 2025 responsibility goals, as highlighted in its latest annual reporting.
  • Since 2020, the company has brought more than four million STEM experiences to students through initiatives like the Regeneron Science Talent Search and International Science and Engineering Fair.
  • Regeneron has committed $300 million from 2017 to 2036 to support premier high school science competitions that have launched successful scientists, technologists, and entrepreneurs.
  • The company ranks in the top 10% of its industry across S&P Global, Sustainalytics, and ISS ESG ratings, validating its leadership in corporate sustainability.
  • Regeneron has earned a place on Newsweek's list of America's Most Responsible Companies for seven consecutive years and TIME's list of the World's Most Sustainable Companies for two consecutive years.
  • The company is utilizing proprietary technologies like VelociSuite® to produce optimized fully human antibodies, accelerating drug development and shaping the next frontier of medicine.
Risk Factors
  • Regeneron announced on May 08, 2026 that it will provide its new gene therapy for a specific form of congenital hearing loss for free in the United States, which may be interpreted as setting a costly precedent that could strain future R&D budgets or profitability.
  • The company's 2030 responsibility goals are introduced without providing any specific financial metrics or revenue targets to support these sustainability commitments, raising questions about the actual economic impact of these initiatives.
Full Analysis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been named to the Dow Jones Best-in-Class World Index for Global Responsibility Leadership for the seventh consecutive year and joined the Dow Jones Best-in-Class North America Index for six consecutive years. Regeneron is among only eight global biotechnology companies and four U.S.-based firms included in these indices, marking a significant recognition of its corporate sustainability performance. This achievement aligns with the company's "Doing Well by Doing Good" philosophy and underscores its commitment to integrating responsibility into all aspects of its business, from drug discovery to operations. The announcement highlights Regeneron's new 2030 science-led responsibility goals, which aim to drive responsible innovation while expanding patient access, exemplified by its decision to provide a novel gene therapy for congenital hearing loss free of charge in the United States. The company released its 2025 Responsibility Report, which details progress on previous targets and showcases how it is meeting or surpassing nearly all its goals while pursuing sustainable growth through homegrown science and proprietary technologies like VelociSuite. Beyond the index recognition, Regeneron emphasizes its major philanthropic initiatives, including the STEM-Fueled™ program, which has provided over four million STEM experiences to students since 2020 through sponsorships of the Regeneron Science Talent Search and International Science and Engineering Fair, backed by a $300 million commitment from 2017 to 2036. The company also highlights the Together for CHANGE™ initiative, a partnership aimed at addressing equity in genomics by sequencing up to half a million volunteers of African ancestry and fostering educational opportunities at institutions like Meharry Medical College. Regeneron further validates its ESG leadership by ranking in the top 10% of its industry across S&P Global, Sustainalytics, and ISS ESG, and appearing on Newsweek's America's Most Responsible Companies list for the seventh year.